Month: October 2020

CAMBRIDGE, Mass. – October 22, 2020 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the presentation of new data on the company’s novel hematopoietic progenitor kinase 1 (HPK1) inhibitors at upcoming scientific conferences.

At the 32^nd EORTC-NCI-AACR Symposium, from October 24-25, 2020, Nimbus will present new in vivo data, including target engagement, tumor growth inhibition, and pharmacodynamics in two mouse syngeneic tumor models (CT26 and B16/F10).

Further, at the Society for Immunotherapy of Cancer’s (SITC) 35^th Anniversary Annual Meeting, from November 9-14, 2020, Nimbus will present new data on in vitro pharmacology and mechanism of action of the HPK1 inhibitors, including effects on T cells, B cells, dendritic cells and antigen presentation.

“Building on the data we presented at AACR earlier this year, we’re pleased to share these new results which provide further support for the anti-tumor immune activity of our small-molecule HPK1 inhibitors,” said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus. “We are progressing towards initiation of IND-enabling studies in the near future, with plans to embark upon first-in-human studies of this novel therapeutic in 2021.”

Details of the presentations are as follows:

EORTC 2020: Pre-recorded presentation with live Q&A

• Title: “A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model”
• Presentation Number: PD-046
• Date & Time: Sun., Oct. 25, 2:50 p.m. CET (9:50 a.m. ET)

SITC 2020: Live presentation

• Title: “A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model”
• Poster Number: 685
• Dates & Times: Weds., Nov. 11, 5:15 p.m. ET; Fri., Nov. 13, 4:40 p.m. ET

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com.

Media Contact

Lisa Raffensperger, (617) 903-8783

Ten Bridge Communications

lisa@tenbridgecommunications.com

DOWNLOAD PRESS RELEASE

CAMBRIDGE, Mass. – October 19, 2020 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the appointment of Erin Cowhig as Chief People Officer. In this newly created role, Ms. Cowhig will oversee all aspects of Nimbus’ human resources, talent acquisition and management, and diversity and inclusion efforts.

“Our people are the reason for Nimbus’ many years of success. With Erin’s leadership as Chief People Officer we are excited to further build our high-performing team, continuing to recruit talented and diverse new Nimbi, develop and invest in our people, and foster a values-driven culture,” said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. “We’re very excited to welcome Erin to the Nimbus team and are confident that her deep experience in human resources, talent acquisition, and diversity and inclusion will contribute to driving Nimbus’ future success.”

Prior to joining Nimbus, Ms. Cowhig was Vice President, Human Resources at Vertex Pharmaceuticals, where she was responsible for HR governance, portfolio management, and organizational effectiveness as well as serving on Vertex’s HR leadership team. Ms. Cowhig was also responsible for leading Vertex’s Diversity and Inclusion strategy. Prior to Vertex, Ms. Cowhig was Senior Director and Head of Talent at Agios Pharmaceuticals, where she led talent acquisition and talent management efforts amidst the company’s transition from a research-focused organization to a late-stage development and commercial company. Ms. Cowhig holds a B.S. in human development and a Master of Industrial and Labor Relations, both from Cornell University.

“Nimbus’ community of passionate, talented people is an incredible asset, and it’s a team I feel privileged to join,” said Ms. Cowhig. “I’m excited to build upon the people-centric culture Nimbus has created to continue to make Nimbus a place of diverse, engaged, top-notch people who are empowered to do their best work and to make a difference in the lives of patients.”

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com.

Media Contact

Lisa Raffensperger, (617) 903-8783

Ten Bridge Communications

lisa@tenbridgecommunications.com

DOWNLOAD PRESS RELEASE

Leading life science investors RA Capital Management and BVF Partners L.P. join Nimbus investor base

CAMBRIDGE, Mass. – October 14, 2020 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the close of a $60 million private financing round from life science investors RA Capital Management and BVF Partners L.P. (“RA” and “BVF”, respectively). The funds support the acceleration of Nimbus’ Phase 1 allosteric tyrosine kinase 2 (TYK2) inhibitor into Phase 2 early next year, its hematopoietic progenitor kinase 1 (HPK1) inhibitor into the clinic next year, as well as the advancement of its preclinical portfolio of new medicines.

“Today’s financing evidences the remarkable success of our structure-based drug discovery approach and the exciting data our pipeline has generated,” said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. “This financing also defines a pathway for our future, and while we could not welcome all the investors with interest in Nimbus into this round, we expect with continued success to build on this financing by bringing on additional new investment in 2021.”

“Nimbus’ compelling TYK2 clinical data clearly positions us for a Phase 2b trial, which will generate data on the same endpoints as BMS’ TYK2 program,” said Bruce Booth, D.Phil., co-founder and Chairman of the Board of Nimbus. “We are fortunate to have RA and BVF join Nimbus, and we welcome Laura Stoppel from RA to the Board.”

“We’re proud to join Nimbus’ circle of investors and to lead this most recent financing round,” said Peter Kolchinsky, Ph.D., a founder and Managing Partner of RA Capital Management. “We see tremendous potential for Nimbus’ lead program, one of only two clinical allosteric approaches to TYK2 inhibition, and for the company’s newly added preclinical programs to address important therapeutic needs in oncology, immunology, and metabolism.”

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com.

Media Contact

Lisa Raffensperger, (617) 903-8783

Ten Bridge Communications

lisa@tenbridgecommunications.com

DOWNLOAD PRESS RELEASE